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06-Benzylguanine enhances the sensitivity of a glioma xenograft with low
06-alkylguanine-DNA alkyltransferase activity to temozolomide and
BCNU
SR Wedge and ES Newlands
Department ofMedical Oncology, Charing Cross Hospital, Fulham Palace Road, London W6 8RF, UK.
Summary The effect of the 06-alkylguanine-DNA alkyltransferase (AGT) inhibitor, 06-benzylguanine (06_
BG), on the anti-tumour activity of 8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazine-4(3H)-one (temozo-
lomide) or 1,3-bis(2-chloroethyl)-nitrosourea (BCNU) was evaluated in athymic mice bearing subcutaneous
(s.c.) human glioma (U87MG) xenografts. The activity ofAGT in U87MG xenografts was 4.3+ 1.5 fmol mg-
protein (mean+s.d.). These xenografts were inherently sensitive to treatment with alkylating compounds alone,
with non-toxic doses of temozolomide (35 mg kg-') or BCNU (10 mg kg-) producing tumour growth delays
of 23.3 and 11.8 days respectively. 06-BG (40 mg kg-) did not inhibit tumour growth when administered
alone, but was found to enhance significantly the anti-tumour activity of temozolomide or BCNU when
administered 1 h before therapy (P<0.002, Mann-Whitney test). AGT activity measured 24 h after the
administration of 40 mg kg-1 06-BG, was only 0.9+0.2 fmol mg-1 protein. These results are in contrast to
previous studies in vitro with tumour cell lines of low AGT activity (< 15 fmol mg protein), in which the
cytotoxicity of temozolomide or BCNU was unaffected by AGT depletion.
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The prognosis for patients with glioblastoma is particularly
poor, given that malignant brain tumours commonly exhibit
intrinsic or acquired resistance to chemotherapy (De Vita,
1989). Conventional treatment for malignant glioma includes
the chloroethylating agent BCNU, which may produce
transient responses, but does little to improve long-term
survival (Steward, 1989). Temozolomide, a methylating
imidazotetrazinone, has recently been found to have greater
activity than BCNU in a number of human brain tumour
xenografts (Friedman et al., 1995) and promising clinical
activity against glioblastoma during phase I and II evaluation
(Newlands et al., 1992; O'Reilly et al., 1993). Nevertheless,
the DNA repair protein AGT, which mediates resistance to
BCNU, can also limit the efficacy of temozolomide
(Catapano et al., 1987). Although the cytotoxicity of BCNU
and temozolomide can be attributed to quite different DNA
lesions, both depend upon initial adduct formation at the o6-
position of guanine (Tong et al., 1982; Tisdale, 1987). o6-
guanine adducts in DNA are removed by AGT in a
stoichiometric reaction, which renders the cytoprotective
protein irreversibly inactive (Pegg, 1990). Since cellular
AGT activity can be restored only by de novo protein
synthesis, its depletion, with a potent inhibitor such as o6-
BG, has been proposed as a useful adjuvant to methylating
or chloroethylating treatment. 06-BG has indeed been found
to enhance the activity of BCNU in many preclinical models
(Dolan et al., 1991; Friedman et al., 1992; Mitchell et al.,
1992; Gerson et al., 1993), and recent studies suggest that
temozolomide can also benefit from 06-BG pretreatment
(Friedman et al., 1995; Wedge et al., 1996). However, it is
generally accepted that the potentiation of methylation or
chloroethylation by 06-BG is proportional to AGT activity,
with no appreciable enhancement of activity in tissues with
low AGT (i.e. < 15 fmol mg-' protein) (Gerson et al., 1988;
Dolan et al., 1991; Plowman et al., 1994). In contrast, this
paper indicates that the activity of both temozolomide and
BCNU can be significantly increased by 06-BG pretreatment,
in a human glioma xenograft with an AGT activity of
<6 fmol mg-
1 protein.
Materials and methods
Chemicals and drugs
Temozolomide was supplied by Dr J Catino, Schering-
Plough Research Institute, Kenilworth, NJ, USA, and
BCNU purchased from Bristol Myers Pharmaceuticals,
Hounslow, Middlesex, UK. 06-BG was a generous gift
from Dr RC Moschel, NCI-Frederick Cancer Research &
Development Center, Frederick, MD, USA, and the
[3H]methyl-labelled DNA substrate for the assay of AGT,
was kindly supplied by Dr GP Margison, Paterson Institute
for Cancer Research, Christie Hospital NHS Trust,
Manchester, UK. Polyethylene glycol (PEG) 400 was
obtained from Brenntag (UK) (Kingston-upon-Thames,
Surrey, UK). All other chemicals were purchased from
Sigma Chemical Co., Poole, UK.
Tumour and mouse model
Athymic MF- 1 (nu/nu genotype) mice were bred in
microisolator cages (PFI Systems, Chesterton, Bicester,
Oxford, UK) at the Charing Cross and Westminster
Medical School, London, UK. Mice were housed in a
barrier facility with 12 h light/dark cycles and provided with
sterilised food and water ad libitum. The human glioblasto-
ma astrocytoma tumour cell line U87MG (Ponten and
Macintyre, 1968), was obtained from the European Tissue
Culture Collection, Porton Down, UK. The cell line was
grown as a monolayer in Dulbecco's modified Eagle medium
(ICN Biomedicals, High Wycombe, UK) supplemented with
10% (v/v) heat-inactivated fetal calf serum (Gibco, Paisley,
UK), L-glutamine (2 mM), penicillin (100 U ml-') and
streptomycin (100 ,Ig ml-'). U87MG was found to be
negative for Sendai virus, mouse hepatitis virus and
pneumonia and minute virus of mice following screening
by a mouse antibody production test (ELISAs were
performed by the Microbiology Laboratories, North
Harrow, Middlesex, UK). Subcutaneous tumour xenografts
were established in the hind flank by injection of 107 cells in
a volume of 0.2 ml of phosphate-buffered saline (PBS).
Xenografts were maintained by serial passage in vivo using
cubic sections of tumour, 1-2 mm in diameter. All
procedures were performed on mice of at least 8 weeks of
age.
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Treatment
Tumour volumes were calculated using the formula for a
prolate ellipsoid (Geran et al., 1972) following in situ
measurement of tumour length and width with digital
calipers (Cole-Palmer Instrument Co., IL, USA). Mice were
randomised and treated (day 1) when tumours reached a
volume of 200-300 mm3. Each compound was administered
as a single intraperitoneal (i.p.) injection at a volume of
100 iil per 10 g of body weight. 06-BG was administered in a
40% solution of PEG 400 in PBS, 1 h before treatment with
BCNU or temozolomide. Solutions of BCNU and temozo-
lomide were prepared immediately before injection, in 10%
ethanol in dextrose (5% w/v) and 10% dimethyl sulphoxide
in PBS respectively. Control animals or animals receiving O6-
BG, temozolomide or BCNU alone also received the
corresponding vehicle(s).
Evaluation of response
Tumour volume and body weight were recorded at two daily
intervals. Tumour response was assessed by the delay in
tumour growth, calculated as the difference in the median
time for tumours in treated and control animals to reach a
volume of 1250 mm3. The statistical significance between
treated and control tumours was evaluated using the
Wilcoxon rank-order test for tumour growth, and differences
between treatments, with/without O-BG, were examined for
statistical significance using a Mann-Whitney test.
AGT assay
Xenograft AGT activity was measured by the removal of O6-
[3H]methylguanine from a [3H]methylated DNA substrate,
using the method of Lee et al. (1991). Protein was determined
using the method of Bradford (1976). All AGT activities are
reported as the mean+s.d.
Table I Effect of temozolomide ±06-BG on the human glioblasto-
ma U87MG grown s.c. in athymic mice
Treatmenta
06-BG Temozolomide Tumour
(mg kg-') (mg kg-') growth delayb
O 0 0.0
0 5 0.9
0 10 14.9*
0 35 23.3**
40 0 0.0
40 5 10.6*
40 10 24.7**
aO6-BG (40 mg kg-1) was administered
1 h before temozolomide.
The relevant vehicle was administered when O6-BG or temozolomide
was not required. bTumour growth delay: the difference between the
median time for tumours in treated and control animals to reach a
volume of 1250 mm3. *P<0.05 and **P<0.0l vs control by Wilcoxon
rank-order test.
Table II Effect of BCNU ± O6-BG on the human glioblastoma
U87MG grown s.c. in athymic mice
Treatmenta
06-BG BCNU Tumour
(mg kg-) (mg kg-') growth delay"
0 0 0.0
0 4 2.5
0 10 11.8*
40 0 0.1
40 1 3.0
40 2 8.9*
40 4 18.0*
aO6-BG was administered 1 h before BCNU. The relevant vehicle
was administered when O6-BG or BCNU was not required. bTumour
growth delay, as Table I. *P<0.0I vs control, by Wilcoxon rank-order
test.
Results
U87MG xenografts used in this study were established from
tumours which had been serially passaged seven times
previously. The AGT activity of these xenografts was
4.3+ 1.5 fmol mg-' protein (n=5, mean+s.d.), which was
similar to that of newly established tumours
(3.0+0.4 fmol mg-' protein). AGT activity remained un-
detectable for at least 5 h following the administration of
40 mg kg-' 06-BG, but was determined to be
0.9+0.2 fmol mg-' protein 24 h after O-BG treatment.
O-BG was administered at the maximum dose which
could be given without inducing any weight loss or mortality
(40 mg kg-1). In contrast, the anti-tumour responses
produced by treatment with temozolomide or BCNU alone
were obtained at only a fraction of the maximum tolerated
doses of 300 mg kg-' and 30 mg kg- respectively (data not
shown).
Tumour growth was not inhibited by the administration of
O-BG (40 mg kg-') with either vehicle solution (Tables I
and II). However, when 06-BG was administered before 5 or
10 mg kg-' temozolomide, a statistically significant
(P<0.002) increase in tumour growth delay was observed
of approximately 10 days (Figure 1, Table I). The growth
delay produced by 10 mg kg-1 temozolomide with 06-BG,
was equivalent to that produced by a 3.5-fold greater dose of
temozolomide alone (Table I). No loss of body weight was
observed with temozolomide alone or in combination with
O-BG, and weight increases were similar to those of control
animals receiving only vehicle solutions.
O-BG also increased tumour responses when administered
before BCNU (Figure 2, Table II): 06-BG combined with
4 mg kg-' BCNU increased tumour growth delay from 2.5 to
18.0 days. Comparison of the tumour growth delay produced
by 4 and 10 mg kg-' BCNU without O-BG, and 1 and
4 mg kg-' BCNU with O-BG (Table II) suggests that the
enhancement of BCNU anti-tumour activity by O6-BG was
between 2.5- and 4-fold. Although no loss in body weight was
produced by 10 mg kg-' BCNU alone, weight losses were
observed when 06-BG was administered before 4 mg kg-'
BCNU with a nadir of -6.0+1.2% (mean+s.d.).
Discussion
The use of 06-BG as a therapeutic adjuvant to methylating or
chloroethylating chemotherapy may be particularly applic-
able to the clinical treatment of glioblastoma, since AGT is
frequently elevated in tumorigenesis of the brain (Silber et al.,
1993; Wiestler et al., 1984).
Although 06-BG has been shown to clearly enhance the
activity of BCNU in a number of human xenograft models
(Friedman et al., 1992; Felker et al., 1993; Sarker et al., 1993;
Dolan et al., 1994), moderate enhancement of temozolomide
activity has previously been demonstrated only once in vivo;
in a medulloblastoma xenograft with an AGT activity of
94.0+30.3 fmol mg-' protein (Friedman et al., 1985). An
additional study investigating a temozolomide and 06-BG
combination suggested that no enhancement of activity could
be obtained in a glioblastoma xenograft with an AGT
activity of 7.4+3.7 fmol mg-' protein (Plowman et al.,
1994). Both of these results correlate with xenograft studies
examining BCNU and O6-BG, which indicate that sensitisa-
tion by 06-BG is greatest in tumours with most AGT (Dolan
et al., 1993). This is also apparent in vitro: depletion of AGT
does not potentiate BCNU or temozolomide cytotoxicity in
tumour cell lines with low AGT activity, including U87MG
(Gerson et al., 1988; Dolan et al., 1991; Wedge et al., 1996).Potentiation of temozolomide and BCNU anti-tumour activity in vivo
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Figure 1 Growth inhibition of U87MG tumour xenografts
treated with 06-BG+temozolomide. Nude mice bearing
U87MG xenografts received i.p. injections of (a) 06-BG vehicle
(40% PEG400 in PBS) h before temozolomide vehicle (10%
DMSO in PBS) (0), 5mgkg- 1 temozolomide (O), 10mgkg-1
temozolomide $A) or 35mgkg-' temozolomide (V), and (b)
40mgkg-1 0 -BG 1 h before temozolomide vehicle (0),
5mgkg- 1 temozolomide (O) or 10mgkg-1 temozolomide (A).
Data points represent the mean (±s.e.) of seven mice.
The enhancement of temozolomide and BCNU activity
observed in this study is therefore particularly surprising, as
the U87MG xenograft had similar AGT activity to that of
the U87MG cell line in vitro (Wedge et al., 1996). These anti-
tumour results are however, corroborated by one other
experiment in which 06-BG increased the anti-tumour
activity of BCNU in a glioma xenograft with no detectable
AGT activity (Felker et al., 1993). That temozolomide and
BCNU activity can be enhanced by 06-BG in vivo, without
any corresponding potentiation in vitro, may suggest that
some efficacy is derived from a pharmacokinetic interaction
with 06-BG. These data also suggest that clinical combina-
tions of 06-BG with methylating or chloroethylating
chemotherapy will result in a greater incidence of toxicity
and/or secondary malignancy (Yarosh, 1985) in normal
tissues with low AGT activity. Nevertheless, 06-BG may
still afford a useful increase in the therapeutic index of
temozolomide and BCNU where AGT-mediated tumour
resistance is apparent (Mitchell et al., 1992; Felker et al.,
1993; Gerson et al., 1993).
Although the activities of temozolomide or BCNU in the
U87MG xenograft were enhanced to a similar extent by o6_
BG, it has been suggested that the U87MG tumour cell line
exhibits additional resistance to chloroethylation that is
unrelated to AGT activity (Wedge et al., 1996). In addition,
single dosing schedules with 06-BG in vitro indicate that
BCNU is potentiated to a greater extent than is temozolo-
mide (Wedge et al., 1996). However, temozolomide is
significantly less toxic than BCNU and demonstrates highly
schedule-dependent anti-tumour activity (Stevens et al.,
1987). Multiple dosing regimens, amenable to methylating
Figure 2 Growth of U87MG tumour xenografts treated with o6_
BG+BCNU. Nude mice bearing U87MG xenografts received i.p.
injections of (a) 06-BG vehicle (40% PEG400 in PBS) 1 h before
BCNU vehicle (10% ethanol in 5% (w/v) dextrose) (0),
4mgkg-
1 BCNU (A\), or l0mgkg-
1 BCNU (C]), and (b)
40mgkg-1 06-BG 1 h before BCNU vehicle (0), 2mgkg
BCNU (V) or 4mgkg-
1 BCNU (A\). Data points represent the
mean (±s.e.) of seven mice.
but not chloroethylating treatment, may therefore offer a
substantial therapeutic advantage. Indeed, the potentiation of
temozolomide cytotoxicity by 06-BG in vitro has been found
to increase linearly with repeat dosing on five consecutive
days (Wedge et al., 1996). A combination of temozolomide
and 06-BG should therefore be considered for clinical
development, particularly for the treatment of central
nervous system tumours which may be more responsive to
temozolomide than BCNU (Friedman et al., 1995).
Abbreviations
Temozolomide, 8-carbamoyl-3-methylimidazo[5, 1-d]-1,2,3,5-tetra-
zine-4(3H)-one, also known as NSC 362856, CCRG 81045 and
SCH 52365; BCNU, 1,3-bis(2-chloroethyl)-nitrosourea (carmus-
tine); AGT, 06-alkylguanine-DNA alkyltransferase (EC 2.1.1.63);
06-BG, 06-benzylguanine.
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